证券研究报告 非金融公司|公司点评|九洲药业（603456） CDMO 短期承压，新业务布局成效初显 glzqdatemark1 证券研究报告 |报告要点 公司发布 2024 年半年报，2024 年上半年公司实现营业收入 27.64 亿元，同比下滑 15.07%； 归母净利润 4.75 亿元，同比下滑 23.62%；扣非归母净利润 4.68 亿元，同比下滑 23.66%。公 司 CDMO 项目管线日益丰富，截止 2024 年 6 月底，拥有 34 个商业化项目、81 个临床 III 期项 目、988 个临床 I/II 期项目，有望持续助推收入稳健增长。 |分析师及联系人 郑薇 SAC：S0590521070002 九洲药业(603456) CDMO 短期承压，新业务布局成效初显 | --- | |-------------------| | 医药生物/医疗服务 | | 买入（维持） | | 12.26 元 | | | | 899.44/898.11 | | 11,010.79 | | 9.33 | | 23.86 | | 30.79/11.83 | 股价相对走势 九洲药业 沪深300 -60% -33% -7 ...

九洲药业（603456.SH）2024 年半年报点评 CDMO 新签及 NDA 项目快速增长，长期发展韧性十足 2024 年 08 月 27 日 ➢ 事件：2024 年 8 月 26 日，九洲药业发布 2024 年半年报。公司上半年实现 营业收入 27.64 亿元，同比下降 15.1%；归母净利润 4.75 亿元，同比下降 23.6%； 扣非净利润 4.68 亿元，同比下降 23.7%。单季度看，Q2 收入 12.89 亿元，同比 下降 14.3%；归母净利润 2.38 亿元，同比下降 30.2%；扣非净利润 2.34 亿元， 同比下降 30.9%。 ➢ CDMO 新签项目及 NDA 项目快速增长，诺欣妥等产品持续放量。上半年， 公司 CDMO 业务收入达 19.71 亿元，同比下降 20.6%；截至 2024H1 商业化项 目 34 个、III 期 81 个、早期临床 988 个，新增项目数同比增长 14%，已递交 NDA 的新药项目数快速增加。诺华 Entresto 延续强劲增长态势，上半年销售额 37.77 亿美元，同比增长 30%，Q2 销售额 18.98 亿美元，同比增长 28%，其中 美国和非美国 ...

Financial Performance - Revenue for the first half of 2024 reached 6.34 billion RMB, representing a year-over-year growth of 18.5%[2] - Net profit attributable to shareholders increased by 22.3% to 1.12 billion RMB compared to the same period last year[2] - Revenue for the first half of 2024 was RMB 2.764 billion, a decrease of 15.07% compared to the same period last year[12] - Net profit attributable to shareholders of the listed company was RMB 474.99 million, down 23.62% year-on-year[12] - Net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, decreased by 23.66% to RMB 467.85 million[14] - Net cash flow from operating activities decreased by 55.55% to RMB 319.52 million[14] - Total assets increased by 2.48% to RMB 11.12 billion[14] - Basic earnings per share decreased by 24.29% to RMB 0.53[14] - Weighted average return on equity decreased by 2.64 percentage points to 5.54%[14] - Revenue for the first half of 2024 was RMB 2.764 billion, a year-on-year decrease of 15.07%[36] - Net profit attributable to the parent company for the first half of 2024 was RMB 475 million, a year-on-year decrease of 23.62%[36] - Revenue decreased by 15.07% to RMB 2,764,279,820.31 compared to the same period last year[54] - Operating costs decreased by 10.67% to RMB 1,790,907,120.13[54] - Management expenses decreased by 25.92% to RMB 197,947,419.63[54] - Financial expenses decreased by 50.74% to RMB -47,612,119.27 due to increased interest income[54] - R&D expenses decreased by 4.20% to RMB 160,008,049.72[55] - Net cash flow from operating activities decreased by 55.55% to RMB 319,524,099.69[55] - Accounts receivable increased by 40.02% to RMB 1,347,373,968.26[56] - Other payables increased by 579.07% to RMB 521,746,622.91 due to increased dividends payable[57] - Overseas assets amounted to RMB 549,169,746.33, accounting for 4.94% of total assets[57] - Restricted assets at the end of the reporting period totaled 357,013,226.76 yuan, including 135,617,217.90 yuan in monetary funds, 69,775,671.94 yuan in fixed assets, and 151,620,336.92 yuan in intangible assets[58] - Total operating revenue for the first half of 2024 was RMB 2,764,279,820.31, a decrease of 15.07% compared to RMB 3,254,642,522.09 in the same period last year[141] - Net profit attributable to the parent company's shareholders was RMB 474,988,640.43, down 23.62% from RMB 621,886,117.33 in the first half of 2023[142] - Basic earnings per share (EPS) for the first half of 2024 was RMB 0.53, a decrease from RMB 0.70 in the same period last year[142] - R&D expenses for the first half of 2024 were RMB 160,008,049.72, a slight decrease of 4.20% compared to RMB 167,026,236.56 in the same period last year[141] - Total comprehensive income for the first half of 2024 was RMB 477,324,339.81, down 23.93% from RMB 627,539,760.63 in the same period last year[142] - Operating profit for the first half of 2024 was RMB 554,674,434.85, a decrease of 22.42% compared to RMB 714,949,160.50 in the same period last year[142] - Interest income for the first half of 2024 was RMB 57,715,485.93, an increase of 93.31% compared to RMB 29,860,706.30 in the same period last year[141] - Total assets impairment loss for the first half of 2024 was RMB -26,268,486.77, a decrease of 49.80% compared to RMB -52,325,556.38 in the same period last year[141] - Parent company's operating income for the first half of 2024 was RMB 616,674,865.90, a decrease of 7.70% compared to RMB 668,142,029.67 in the same period last year[145] - Parent company's net profit for the first half of 2024 was RMB 227,677,532.67, an increase of 194.73% compared to RMB 77,245,013.99 in the same period last year[145] - Comprehensive income for the first half of 2024 reached 227,677,532.67 RMB, a significant increase from 77,245,013.99 RMB in the same period last year[146] - Cash received from sales of goods and services in the first half of 2024 was 2,222,642,259.36 RMB, down from 2,782,970,629.40 RMB in the same period last year[147] - Net cash flow from operating activities for the first half of 2024 was 319,524,099.69 RMB, compared to 718,866,085.42 RMB in the same period last year[148] - Net cash flow from investing activities for the first half of 2024 was -494,504,607.87 RMB, an improvement from -534,593,660.55 RMB in the same period last year[148] - Net cash flow from financing activities for the first half of 2024 was -82,796,669.56 RMB, a significant decrease from 3,096,100,953.75 RMB in the same period last year[148] - Cash and cash equivalents at the end of the first half of 2024 were 2,823,668,627.24 RMB, down from 3,963,910,388.58 RMB at the end of the same period last year[149] - Cash received from sales of goods and services by the parent company in the first half of 2024 was 429,511,734.87 RMB, down from 654,607,845.90 RMB in the same period last year[150] - Net cash flow from operating activities for the parent company in the first half of 2024 was 13,511,954.86 RMB, a significant decrease from 559,053,527.71 RMB in the same period last year[150] - Net cash flow from investing activities for the parent company in the first half of 2024 was -455,510,199.80 RMB, an improvement from -1,369,770,926.19 RMB in the same period last year[150] - Cash and cash equivalents at the end of the first half of 2024 for the parent company were 2,823,668,627.24 RMB, down from 3,963,910,388.58 RMB at the end of the same period last year[149] - Cash and cash equivalents at the end of the period amounted to 1,784,754,017.44 RMB, a decrease of 10.9% compared to the previous period[151] - Net cash flow from financing activities was 1,490,927,945.04 RMB, a decrease of 43.7% compared to the previous period[151] - Total owner's equity at the end of the period was 8,468,268,766.73 RMB, a decrease of 0.8% compared to the beginning of the period[153] - Comprehensive income for the period was 476,699,422.99 RMB, a decrease of 24.0% compared to the previous period[153] - Total cash outflow for financing activities was 828,572,054.96 RMB, an increase of 122.5% compared to the previous period[151] - Cash paid for debt repayment was 700,000,000.00 RMB, an increase of 125.8% compared to the previous period[151] - Cash paid for dividends, profits, or interest payments was 12,791,218.25 RMB, an increase of 53.8% compared to the previous period[151] - Cash paid for other financing activities was 115,780,836.71 RMB, an increase of 114.5% compared to the previous period[151] - Net increase in cash and cash equivalents was 1,049,498,136.43 RMB, a decrease of 43.3% compared to the previous period[151] - Total owner's equity at the beginning of the period was 8,533,070,893.21 RMB, a decrease of 0.8% compared to the previous period[153] - The company's total owner's equity at the end of the first half of 2024 was RMB 6,184,601,422.25, a decrease of RMB 315,326,837.78 compared to the beginning of the period[159] - The company's comprehensive income for the first half of 2024 was RMB 227,677,532.67[158] - The company's capital reserve increased by RMB 1,137,663.70 during the first half of 2024[158] - The company's undistributed profit decreased by RMB 217,709,681.33 in the first half of 2024[158] - The company's total owner's equity at the end of the first half of 2024 was RMB 5,905,768,107.92, an increase of RMB 2,180,022,120.65 compared to the beginning of the period[161] - The company's comprehensive income for the first half of 2024 was RMB 77,245,013.99[160] - The company's capital reserve increased by RMB 2,432,463,172.35 during the first half of 2024[160] - The company's undistributed profit decreased by RMB 281,403,517.21 in the first half of 2024[160] Business Segments and Operations - The CDMO business segment contributed 4.56 billion RMB, accounting for 71.9% of total revenue[2] - The company expanded its production capacity with a new facility in Taizhou, adding 15,000 square meters of manufacturing space[2] - International sales grew by 20.8% to 3.78 billion RMB, representing 59.6% of total revenue[2] - The company signed 12 new CDMO projects in H1 2024, with a total contract value of 1.2 billion RMB[2] - The company plans to invest 800 million RMB in new technology development for advanced drug delivery systems[2] - The company's subsidiaries include Raybow (US) Pharmaceutical Company Inc, a wholly-owned subsidiary of Zhejiang Raybow[10] - The company's subsidiaries span across multiple regions including Suzhou, Hangzhou, Singapore, and the United States[10] - The company's subsidiaries are involved in pharmaceutical manufacturing, biotechnology, and animal health products[10] - The company's subsidiaries include Raybow Life Sciences (Singapore) PTE. LTD, a wholly-owned subsidiary[10] - The company's subsidiaries include Jiuzhou Overseas (Hong Kong) Limited, a wholly-owned subsidiary[10] - The company's subsidiaries include Jiuzhou Pharma Lab Co., Ltd, a wholly-owned subsidiary of Raybow Singapore[10] - The company is a leading CDMO enterprise, providing services to global pharmaceutical companies such as Novartis, Roche, and Gilead[18] - The company's CDMO business focuses on small molecule drugs, peptide drugs, and oligonucleotide drugs, with projects in areas like oncology and diabetes[18] - The company has established over 550 enzymes covering more than a dozen reaction types, successfully developing 35 enzyme-catalyzed synthesis processes, with several achieving ton-scale production[25] - The company has developed a library of over 100 chiral ligands for catalyst libraries, applied in the process development of chiral drugs for multinational pharmaceutical companies[24] - The company has achieved ton-scale commercial production using continuous flow reaction technology, with extensive experience in Grignard exchange, low-temperature reactions with lithium reagents, and diazotization reactions[25] - The company has developed a library of linkers, including the top 10 linkers and their derivatives used in approved drugs, and has established a toxin library and chelator library[26] - The company has built OEB4 and OEB5 level high-activity laboratories and GMP high-activity workshops, capable of providing single-batch production services from milligrams to hundreds of grams[27] - The company has established a matrix-style project implementation management team covering the entire project lifecycle, providing end-to-end services for global pharmaceutical companies, biotech firms, and research institutions[28] - The company has developed a "iron triangle" business development model, centered around customer managers, solution managers, and delivery managers, to enhance customer satisfaction and loyalty[28] - The company has successfully developed a continuous flow commercial process for key intermediates of innovative drugs, capable of producing hundreds of tons of oxidation reagents annually[38] - The company has delivered over 10 customer products using its proprietary synthetic methods for chiral non-natural amino acids and alkylation modifications[38] - The company has developed multiple fluorine reagents and fluorine-containing molecular blocks, leveraging its expertise in fluorine chemistry[38] - The company has collaborated with Zhejiang University of Technology to develop new synthetic methods for multi-substituted ring compounds and bridged ring compounds[38] - The company has successfully built and tested a continuous photochemical reaction device capable of producing hundreds of grams of product[38] - The company has applied for 5 patents and published 2 papers in international journals related to photoelectrochemical technology[38] - The company has established a comprehensive cGMP quality management system, passing inspections by major global regulatory agencies such as NMPA, FDA, and EDQM[32] - The company has implemented an EHS management system recognized by top international pharmaceutical companies, focusing on safety, green practices, and health maintenance[33] - The company developed over 80 new types of enzymes and obtained 2 patents for enzyme evolution, with 1 new patent application in progress[39] - The solid-state research platform undertook over 20 innovative drug projects, including polymorph screening, salt/cocrystal screening, and crystallization process development, with 1 new patent application for crystallization technology[39] - The TIDES division was established, leveraging non-classical solid-phase synthesis technology to significantly reduce production costs and enhance product competitiveness[40] - The company completed the construction of small nucleic acid drug R&D platforms in both the US and China, and is accelerating the development of GMP pilot production and commercial-scale facilities[40] - The company has nearly 100 ongoing formulation projects, with 49 patent applications filed, of which 25 have been granted[41] - The company's formulation CDMO services grew by 32% in project volume and over 50% in revenue, serving over 60 clients and introducing nearly 20 new clients[47] - The company's CDMO project pipeline includes 34 marketed projects, 81 Phase III clinical projects, and 988 Phase I/II clinical projects, covering therapeutic areas such as oncology, heart failure, and central nervous system disorders[45][46] - The company expanded its global CDMO capacity with new facilities in Japan and Germany, and upgraded existing facilities to enhance automation and multifunctionality[49] - The company's peptide platform received multiple customer orders, including peptide-based diabetes and lung cancer drugs, with the TIDES division expected to drive further growth[48] - The company is focusing on green manufacturing and automation, applying enzyme catalysis and continuous processing technologies to improve product quality and reduce costs[49] - The company established a wholly-owned subsidiary in Japan with an investment of JPY 119,497,702.00 (approximately USD 4.2 million) to build a CRO service platform[60][61] - The company plans to establish a wholly-owned subsidiary in Germany with an estimated total investment of USD 9.5 million for a R&D service platform[62] - Zhejiang Ruibo Pharmaceutical Co., Ltd., a major subsidiary, reported total assets of 319,013.47 million yuan, revenue of 97,500.20 million yuan, and net profit of 19,852.82 million yuan[63] - Jiangsu Ruike Pharmaceutical Technology Co., Ltd., another subsidiary, reported a net loss of 4,373.02 million yuan[63] Market and Industry Trends - The global pharmaceutical market is projected to reach USD 2.3 trillion by 2027, with a CAGR of 5-8% from 2024 to 2028[21] - The global pharmaceutical CDMO market reached $63.2 billion in 2021, with a projected CAGR of 18.5%, expected to reach $124.3 billion by 2025[22] - The global API market was $211 billion in 2022, with a CAGR of 6.5%, projected to reach $349.2 billion by 2030[22] Risks and Challenges - The company faces risks related to the withdrawal or recall of major innovative drugs it services, which could reduce demand for its products and R&D services[64] - The company is exposed to risks from the lifecycle changes of innovative drugs, including potential sales below expectations and competition from generic drugs[65] - There is a risk of technological upgrades in the specialty API business, which could impact the company's competitiveness if competitors adopt advanced technologies first[66] - The company faces regulatory risks due to changes in drug regulatory policies and increased scrutiny from authorities, which could affect its operations and market access[67] - The company has established or acquired multiple enterprises to advance global business development, relying on compliance with local laws and regulations in various countries and regions[68] - The company faces increased competition from new domestic entrants and accelerated investments by European and American pharmaceutical custom R&D and production enterprises in China[69] - The company's overseas business accounts for a high proportion, with USD and EUR as the main settlement currencies, and faces significant exchange rate fluctuation risks[71] - The company has implemented a flexible pricing mechanism with overseas clients and uses hedging tools to manage exchange rate risks[71] - The company's production process generates wastewater, exhaust gases, waste residues, and other pollutants, posing environmental and safety risks[70] - The company has established an EHS management system based on international best practices to address environmental, health, and safety concerns[70] Environmental and Sustainability - The company is listed as a key pollutant discharge unit by environmental protection authorities[81] - Wastewater discharge of

证券代码：603456 证券简称：九洲药业 公告编号：2024-066 浙江九洲药业股份有限公司 关于变更回购股份用途并注销的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次变更回购股份用途：浙江九洲药业股份有限公司（以下简称"公司" 或"九洲药业"）拟将 2022 年股份回购方案的股份用途由"用于后续实施股权激 励计划"变更为"用于注销并减少公司注册资本"。 本次拟注销股份数量：2,871,000 股，占公司目前总股本的 0.32%。 本次变更回购股份用途并注销事项尚需提交公司股东大会审议通过后 实施。 公司于 2024 年 8 月 26 日召开了第八届董事会第九次会议，审议通过了《关 于变更回购股份用途并注销的议案》，拟对公司 2020 回购方案的股份进行用途变 更并注销，现就相关情况公告如下： 一、公司回购方案情况 公司于 2022 年 8 月 31 日召开第七届董事会第二十一次会议，审议通过了《关 于以集中竞价交易方式回购公司股份的议案》，同意公司使用自有资金以集中竞 价交易方式回购公司股份用 ...

浙江九洲药业股份有限公司 章 程 二〇二四年八月 | 第一章 | 总 则 | 2 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 3 | | 第三章 | 股 份 | 3 | | 第一节 | | 股份发行 3 | | 第二节 | | 股份增减和回购 4 | | 第三节 | | 股份转让 5 | | 第四章 | 股东和股东大会 | 6 | | 第一节 | | 股东 6 | | 第二节 | | 股东大会的一般规定 8 | | 第三节 | | 股东大会的召集 10 | | 第四节 | 股东大会的提案与通知 | 11 | | 第五节 | | 股东大会的召开 13 | | 第六节 | 股东大会的表决和决议 | 16 | | 第五章 | 董事会 | 20 | | 第一节 | 董 事 | 20 | | 第二节 | 董事会 | 23 | | 第六章 | 总裁及其他高级管理人员 | 28 | | 第七章 | 监事会 | 29 | | 第一节 | 监 | 事 29 | | 第二节 | | 监事会 30 | | 第八章 | | 党建工作 31 | | 第九章 | 财务会计制度、利润分配和审计 | 32 ...

监事会对董事会编制的公司 2024 年半年度报告进行了认真审核，认为： 证券代码：603456 证券简称：九洲药业 公告编号：2024-062 浙江九洲药业股份有限公司 第八届监事会第五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 浙江九洲药业股份有限公司（以下简称"公司"）第八届监事会第五次会议 于 2024 年 8 月 26 日以现场表决结合通讯表决的方式召开。本次监事会已于 2024 年 8 月 16 日以电子邮件、电话、传真等方式通知全体董事、监事、高级管理人 员。会议由孙蒙生先生主持，会议应出席监事 3 名，实际出席监事 3 名。本次会 议参与表决人数及召集、召开程序符合《公司法》和《公司章程》的有关规定， 合法有效。 二、监事会会议审议情况 1、审议通过了《关于公司 2024 年半年度报告全文及摘要的议案》； （1）公司 2024 年半年度报告的编制和审议程序符合相关法律、法规、规章 和《公司章程》以及公司内部管理制度的相关规定； （2）公司 2024 年半年度报告的内容和 ...

证券代码：603456 证券简称：九洲药业 公告编号：2024-068 浙江九洲药业股份有限公司 关于召开 2024 年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一)股东大会类型和届次 2024 年第一次临时股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2024 年 9 月 18 日 14 点 00 分 召开地点：浙江九洲药业股份有限公司会议室（浙江省台州市椒江区外沙路 99 号） (五)网络投票的系统、起止日期和投票时间。 股东大会召开日期：2024年9月18日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 9 月 18 日 不适用。 二、 会议审议事项 本次股东大会审议议案及投票股东类型 | 序号 | 议案名称 | ...

浙江天册律师事务所 关于 法律意见书 浙江九洲药业股份有限公司 终止实施 2021 年限制性股票激励计划有关事项之 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 邮编 310007 关于浙江九洲药业股份有限公司 终止实施 2021 年限制性股票激励计划有关事项之 法律意见书 编号：TCYJS2024H1341号 致：浙江九洲药业股份有限公司 浙江天册律师事务所（以下简称"本所"）接受浙江九洲药业股份有限公司 （以下简称"公司"或"九洲药业"）的委托，就公司实施 2021 年限制性股票 激励计划（以下简称"本次激励计划"）有关事项担任专项法律顾问，并依据《中 华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管 理办法》"）等有关法律、法规和规范性文件及九洲药业《公司章程》的相关规 定，已出具了 TCYJS2021H0711 号《浙江天册律师事务所关于浙江九洲药业股份 有限公司 2021 年限制性股票激励计划的法律意见书》、TCYJS2021H0831 号《浙 江天册律师事务所关于浙江九洲药业股份有限公司 ...

公司于 2024 年 1 月 4 日召开第八届董事会第二次会议、第八届监事会第二 次会议审议通过了《关于使用部分闲置募集资金临时补充流动资金的议案》，同 意公司及其子公司拟使用 2020 年非公开发行募集资金中不超过人民币 1.55 亿元 的部分闲置募集资金临时补充公司流动资金，仅限于与公司主营业务相关的生产 经营使用，在上述额度内，资金可滚动使用。使用期限自第第八届董事会第二次 会议审议通过之日起不超过 12 个月。具体内容详见公司于 2024 年 1 月 5 日在 《上海证券报》和上海证券交易所网站（www.sse.com.cn）披露的相关公告（公 告编号：2024-002）。 截至 2024 年 4 月 8 日，公司 2020 年非公开发行募集资金用于临时补充流动 资金的募集资金中尚未归还的金额为 1.40 亿元，具体内容详见公司于当日在《上 海证券报》和上海证券交易所网站（www.sse.com.cn）披露的相关公告（公告编 号：2024-017）；2024 年 8 月 23 日，公司将上述用于临时补充流动资金的 6,000 万元募集资金提前归还至募集资金专户。同时公司已按照法律法规要求，将上述 募集 ...

证券代码：603456 证券简称：九洲药业 公告编号：2024-059 浙江九洲药业股份有限公司 关于召开 2024 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 1、会议召开时间：2024 年 8 月 28 日（星期三）16:00-17:00 2 、 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开时间：2024 年 8 月 28 日（星期三）16:00-17:00 会议召开方式：上证路演中心网络互动 3、会议召开方式：上证路演中心网络互动 重要内容提示： 会议召开地点： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 投资者可于 2024 年 8 月 21 日（星期三）至 8 月 27 日（星期二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （603456@jiuzhou ...